Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl

Refine search results

Preferences help
enabled [disable] Abstract
Number of results

Results found: 1

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  DNA RECOMBINATION
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
EN
The ability of human and animal immunological system to generate many hundreds of millions of antibodies with different variable-region domains allows to bind other proteins, peptides and low molecular weight haptens despite the enormous variety of chemical and physical structures that these entities can represent. The prediction of Paul Ehrlich in 1900 an age of 'magic bullet applications in human therapeutics is now being realized. Hybrydoma technology introduced in 1975 was crucial event for immunology and biotechnology, providing large amounts of specific monoclonal antibodies (Mab) for basic research, immunodiagnosis, serotherapy and industrial processes. During last 20 years significant progress has been made in production of Mab or Mab fragments by DNA recombination techniques and expression in bacteria, yeast, mammalian cells and transgenic animals and plants. The rapid isolation of high affinity human Mab from phage display libraries and by immunization of transgenic mice will facilitate the development of therapeutic antibodies. It become also clear that antibodies and antibody fragments are playing increasing contribution not only to pharmaceutical but also to food, cosmetic and chemical industries, as well as to environmental protection.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.